Associations of plasma soluble CD22 levels with brain amyloid burden and cognitive decline in Alzheimer’s disease

XL Bu; PY Sun; DY Fan; J Wang; HL Sun; Y Cheng; GH Zeng; DW Chen; HY Li; X Yi; YY Shen; LA Miles; P Maruff; BJ Gu; CJ Fowler; CL Masters; YJ Wang

Journal article

Associations of plasma soluble CD22 levels with brain amyloid burden and cognitive decline in Alzheimer’s disease

XL Bu, PY Sun, DY Fan, J Wang, HL Sun, Y Cheng, GH Zeng, DW Chen, HY Li, X Yi, YY Shen, LA Miles, P Maruff, BJ Gu, CJ Fowler, CL Masters, YJ Wang

Science Advances | AMER ASSOC ADVANCEMENT SCIENCE | Published : 2022

DOI: 10.1126/sciadv.abm5667

Abstract

CD22 has been suggested to contribute to Alzheimer’s disease (AD) pathogenesis by inhibiting microglial amyloid β (Aβ) phagocytosis. Soluble CD22 (sCD22) generated by cleavage from cell membranes may be a marker of inflammation and microglial dysfunction; but alterations of sCD22 levels in AD and their correlation with AD biomarkers remain unclear. Plasma sCD22 levels were measured in cognitively normal non-AD participants and patients with preclinical AD and AD dementia from a Chinese cohort and the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing. Plasma sCD22 levels were elevated in patients with preclinical and dementia AD. Plasma sCD22 levels were negatively correla..

View full abstract

University of Melbourne Researchers

Paul Maruff Author

Grants

Awarded by Alzheimer's Association

Funding Acknowledgements

The Chongqing cohort study was supported by the National Natural Science Foundation of China (82122023, 81930028, and 31921003), the National Key R&D Program of China (2018YFA0109600), and the Natural Science Foundation of Chongqing, China (cstc2020jcyj-msxmX0132). The AIBL study (www.aibl.csiro.au), a consortium between Austin Health, CSIRO, Edith Cowan University, and the Florey Institute (The University of Melbourne), has received partial financial support from the Alzheimer's Association (United States), the Alzheimer's Drug Discovery Foundation, the McCusker Alzheimer's Research Foundation, the National Health and Medical Research Council, and the Yulgilbar Foundation. Numerous commercial interactions have supported data collection and analysis. In-kind support was also provided by the Sir Charles Gairdner Hospital, CogState Ltd., Hollywood Private Hospital, the University of Melbourne, and St Vincent's Hospital.